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Treatment-Related Upper Limb Morbidity 1 Year after Sentinel
Lymph Node Biopsy or Axillary Lymph Node Dissection for
Stage I or II Breast Cancer
J. S. Rietman, MD, P. U. Dijkstra, PT, MT, PhD, J. H. B. Geertzen, MD, PhD,
P. Baas, MD, PhD, J. de Vries, MD, PhD, W. V. Dolsma, MD, PhD,
J. W. Groothoff, MSc, PhD, W. H. Eisma, MD, and H. J. Hoekstra, MD, PhD
Background: In a prospective study, upper limb morbidity and perceived disability/activities of
daily life (ADLs) were assessed before and 1 year after sentinel lymph node biopsy (SLNB) or
axillary lymph node dissection (ALND).
Methods: A total of 204 patients with stage I/II breast cancer (mean age, 55.6 years; SD, 11.6
years) entered the study, and 189 patients (93%) could be evaluated after 1 year. Fifty-eight patients
(31%) underwent only SLNB, and 131 (69%) underwent ALND. Assessments performed before
surgery (t0) and 1 year after surgery (t1), included pain, shoulder range of motion, muscle strength,
upper arm/forearm circumference, and perceived shoulder disability/ADL.
Results: Considerable treatment-related upper limb morbidity was observed. Significant (P 
.05) changes between t0 and t1 were found in all assessments except strength of elbow flexors.
Patients in the ALND group showed significantly more changes in the range of motion in forward
flexion, abduction, and abduction/external rotation; grip strength and strength of shoulder abductors;
circumference of upper arm and forearm; and perceived shoulder disability in ADLs compared with
the SLNB group. Multivariate linear regression analysis showed that ALND could predict a decrease
of range of motion in forward flexion, abduction, strength of shoulder abductors, grip strength, and
shoulder-related ADLs and an increase in the circumference of the upper arm. Radiation of the axilla
(19 patients) predicts an additional decrease in shoulder range of motion.
Conclusions: One year after treatment of breast cancer, there is significantly less upper limb
morbidity after SLNB compared with ALND. ALND is a predictor for upper limb morbidity.
Key Words: Breast cancer—Staging—Sentinel lymph node—Axillary dissection—Radiation—
Morbidity.
The aim of modern breast cancer treatment is to obtain
local tumor control, optimal lymph node staging with
minimal treatment-related morbidity, good functional re-
sults, and, when possible, preservation of the breast.
Axillary lymph node status is an important prognostic
factor in patients with breast cancer.1–4 Axillary lymph
node dissection (ALND), however, is associated with
upper limb morbidity such as pain, numbness, lymphed-
ema, weakness, and impaired shoulder range of mo-
tion.5–12 Upper limb morbidity can affect the ability to
perform activities of daily life (ADLs) and quality of
life.11–18 Sentinel lymph node biopsy (SLNB) was intro-
duced for staging of the axilla to reduce the number of
unnecessary ALNDs.19 SLNB is an accurate and safe
procedure to predict metastatic disease in axillary lymph
nodes and is widely accepted in breast cancer treat-
ment.19–23 SLNB is an excellent alternative for ALND in
patients with clinically negative lymph nodes.24 An in-
creasing number of studies have evaluated SLNB-related
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morbidity in comparison with ALND-related morbidi-
ty.22,23,25–35 Most of these studies have reported less
morbidity for SLNB than for ALND.23,25–36 A shortcom-
ing in most studies is the absence of pretreatment
assessment.
Fewer studies have investigated upper limb morbidity
and perceived disability in ADLs after SLNB in compari-
son to ALND.26,30,33 Generally, disability in ADLs of the
SLNB group was less than for the ALND group.26,30,33
The aim of this study was to analyze prospectively the
upper limb morbidity and perceived disability in ADLs
of patients 1 year after SLNB versus ALND. Second-
arily, it analyzed to which extent ALND and other treat-
ment variables could predict upper limb morbidity and
perceived disability.
PATIENTS AND METHODS
From June 1999 to June 2001, patients with breast
carcinoma stage I or II participated in the study.37 Pa-
tients were recruited from the University Hospital Gro-
ningen and the Martini Hospital Groningen. Informed
consent was obtained from the participating patients. The
protocol was approved by the institutional review boards
of both hospitals. Two groups of breast cancer patients
participated in the prospective study: patients who un-
derwent conventional breast cancer treatment with
ALND and patients who were treated according to the
SLNB concept. Patients with positive sentinel lymph
nodes subsequently received an ALND and were in-
cluded in the ALND group.
Sentinel lymph nodes were identified by preoperative
lymphoscintigraphy followed by intraoperative tracing
with a gamma probe and Patent blue dye® (Blue Patente´,
Labatoire Guerbet, Aulnay-sous-Bois, France). The pro-
cedure has been previously described in detail.38 If
pathologic examination revealed metastases in the senti-
nel lymph node, ALND was performed within 2 weeks
after SLNB. Surgical and adjuvant treatments were used
according to our protocol in both groups (Table 1).
Upper limb function and ADLs were assessed 1 day
before surgery (t0) and 1 year after surgery (t1). Pain was
assessed with a visual analog scale (VAS; Table 2).
Patients were asked to mark their current pain on a 10-cm
straight line (0 cm, no pain; 10 cm, worst pain imagin-
able).39,40 Upper limb function was assessed by means of
a physical examination according to a protocol (Table 2).
Active shoulder range of motion was measured with a
goniometer according to a standardized protocol in for-
ward flexion, abduction, and external rotation.40,41 Mus-
cle strength of shoulder abductors and elbow flexors was
measured with a handheld dynamometer (Citec®, Gro-
ningen, The Netherlands).42–44 For assessment of grip
strength, a Yamar® handheld dynamometer (Bolling-
brook, Illinois, USA) was used.45,46 All muscle strength
measurements were performed three times, and the mean
of these three measurements was used for further analy-
sis. Upper arm and forearm circumferences were mea-
sured with a Gulick Measuring Tape® (Lafayette Instru-
ments; model 258-J00305, Lafayette, Indiana, USA) at
10 cm proximal to the olecranon and 15 cm proximal to
the styloid process of the ulnae.
ADLs were assessed with the Shoulder Disability
Questionnaire (SDQ) and the Groningen Activity Re-
striction Scale (GARS). The SDQ is a functional status
measure that covers 16 items. It was designed to evaluate
TABLE 1. Tumor-node-metastasis classification, receptor status, and treatment characteristics of the included patients
Variable SLNB (n  66) ALND (n  138) Total (n  204)
Patient age, y, mean (SD) 57.0 (11.9) 54.9 (11.3) 55.6 (11.6)
Tumor-node-metastasis classification
Stage I 46 (70) 39 (28) 85 (42)
Stage IIA 15 (23) 71 (51) 86 (42)
Stage IIB 5 (8) 28 (20) 33 (16)
Estrogen-receptor status
Positive 38 (58) 96 (70) 134 (66)
Negative 28 (42) 42 (30) 70 (34)
Surgical treatment of breast
Mastectomy 17 (26) 68 (49) 85 (42)
Lumpectomy 49 (74) 70 (51) 119 (58)
Adjuvant therapies
Radiotherapy of breast 49 (74) 70 (51) 119 (58)
Radiotherapy of axilla 0 (0) 19 (14) 19 (9)
Chemotherapy 10 (15) 59 (43) 69 (34)
Hormonal therapy 10 (15) 68 (49) 78 (38)
Data are n (%) unless otherwise noted.
SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.
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the ability to perform daily activities in patients with
shoulder disorders (shoulder-related ADLs).47,48 It con-
tains 16 statements that patients with shoulder disorders
have used to describe in what kind of ADL situations
they experience pain. It has a three-category response
format: for example, 1, “Yes, my shoulder is painful
when I open or close a door”; 2, “No, my shoulder is not
painful when I open or close a door”; and 3, “I did not
perform the activity during the past 24 hours.” The total
scoring range for the 16 statements was transformed to 0
to 100. A score of 0 means no functional status limita-
tion, and a score of 100 means maximum functional
status limitation (Table 2).47,48
The GARS assesses the perceived restrictions (disabil-
ity) in performing 18 ADLs.49,50 It has a four-category
response format: 1, able to perform the activity without
any difficulty; 2, able to perform the activity with some
difficulty; 3, able to perform the activity with much
difficulty; and 4, unable to perform the activity indepen-
dently. The scoring range is 18 to 72. With a score of 18,
the person can perform all the activities without any
difficulty; with a score of 72, the person cannot perform
any activity without the help of others (Table 2).49,50
Statistical analyses included descriptive statistics and
t-tests for independent samples for between-group com-
parisons and t-tests for dependent samples for within-
group comparisons. Pearson’s 2 test was used for di-
chotomous variables. To discern to what extent treatment
variables could predict upper limb morbidity and per-
ceived disability, multivariate linear regression analyses
were performed with the following independent vari-
ables: ALND, surgical treatment of the breast (modified
radical mastectomy or lumpectomy), radiation of the
axilla, and radiation of the breast. Differences were ac-
cepted as significant if P values were .05.
RESULTS
From 1999 to 2001, 204 consecutive patients with
invasive breast carcinoma were included in the study.
Initially 124 patients (61%) underwent an SLNB; 58
patients (47%) subsequently underwent additional
ALND because of metastasis in the sentinel node. There-
fore, the study consisted of 66 patients (32%) with an
SLNB and 138 patients (68%) with a level I or II ALND.
Tumor-node-metastasis classification, receptor status,
and treatment characteristics of the patients are listed in
Table 1. At t1, 189 patients could be evaluated: 58
patients (31%) in the SLNB group and 131 patients
(69%) in the ALND group. Fifteen patients (7%) could
not be assessed after 1 year. Seven patients were from the
ALND group: two patients died of metastatic disease,
two withdrew from the study because of distant metas-
tases, and three withdrew because of psychological bur-
den. Eight patients belonged to the SLNB group; one
patient had distant metastasis, one refused further treat-
ment, and six found the assessment protocol bothersome
and chose to withdraw from the study although they had
no upper limb complaints.
After 1 year, substantial treatment-related upper limb
morbidity was observed for the entire study group (n 
189). Significant changes between t0 and t1 were found
in all assessments except strength of the elbow flexors
(Table 3). There was a small but significant increase in
self-assessed pain perception (VAS) from .4 (SD, 1.1) to
.8 (SD, 1.5). Numbness of the axillary region was ob-
served in 119 patients (63%). The largest decrease in
range of motion of the shoulder was found in abduction
(15.7°; SD, 28.8°). Decreases in grip strength (16.8 Nm;
SD, 48.0 Nm) and muscle strength of the shoulder ab-
ductors (11.4 Nm; SD, 31.9 Nm) were observed. At t1,
there was a minor but significant increase of upper arm
circumference (.7 cm; SD, 1.7 cm) and forearm circum-
ference (.4 cm; SD, 1.0 cm).
TABLE 2. Assessment of shoulder function and activities
of daily life (ADLs)
Assessment Assessment tool
Shoulder function
Pain (current pain) VAS39,40 (cm)
Numbness Clinical examination:
numbness, yes or no



























VAS, visual analog scale; SDQ, Shoulder Disability Question-
naire47,48; GARS, Groningen Activity Restriction Scale.49,50
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Disability/ADLs increased as assessed with the SDQ
(10.7; SD, 29.2) and the GARS (1.5; SD, 4.6; Table 3).
Several changes in upper limb function (upper limb mor-
bidity) and ADLs (perceived disability) between t0 and t1
were significantly different between the SLNB group and
the ALND group, in favor of the first (Table 4).
No significant difference was found for the change in
pain perception of both groups (Table 4). Numbness was
observed in 10 patients (17%) of the SLNB group and in
109 patients (83%) of the ALND group at t1 (P  .001;
2 test). For range of motion of the shoulder, the largest
difference was found in shoulder abduction (14.5°; 95%
confidence interval [CI], 22.0°–7.1°; Table 4). No dif-
ference was found in external rotation between groups.
Significant differences were observed for grip strength
(25.6 Nm; 95% CI, 40.8–10.3 Nm), strength of the
shoulder abductors (14.9 Nm; 95% CI, 23.5–6.3 Nm),
and, to a minor extent, strength of the elbow flexors
(Table 4). The differences in circumference of the upper
arm and forearm were significant (upper arm, .6 cm;
95% CI, .1–1.1 cm; forearm, .3 cm; 95% CI, .1–.6 cm;
Table 4). Considering the increase in perceived disability
in ADLs, a significant difference between the SLNB
group and the ALND group was found for the SDQ
(10.6; 95% CI, 2.5–18.7) but not for the GARS (1.0; 95%
CI, .1 to 2.1).
Multivariate linear regression analysis was performed
to predict the mean change in upper limb function and
TABLE 4. Change of upper limb function and disability in the SLNB group and the ALND group between t1 (12 months after
surgery) and t0 (before surgery)
Variable
SLNB (n  58)
(t1  t0)
(mean change  SD)
ALND (n  131)
(t1  t0)
(mean change  SD)
Differences in mean change,
ALND  SLNB
Mean difference P value
Pain (VAS: 0–10) .2 1.2 .6  1.9 .4 .073
Numbness (n)a 10 109 99 .001
Forward flexion (°) 2.7  10.0 7.7  13.7 5.0 .005
Abduction (°) 5.6  20.2 20.1  30.9 14.5 .001
Abduction/external rotation (°) 4.6  7.9 8.9  15.0 4.3 .011
External rotation (°) 4.6  12.3 6.6  12.8 2.0 .324
Strength of shoulder abductors (Nm) 1.0  24.0 15.9  33.9 14.9 .001
Strength of elbow flexors (Nm) 7.5 28.3 3.3  44.3 10.8 .048
Grip strength (Nm) .0 45.9 25.6  50.0 25.6 .001
Circumference of upper arm (cm) .3 1.2 .9  1.8 .6 .019
Circumference of forearm (cm) .2 .7 .5  1.0 .3 .009
SDQ (0–100) 3.4 23.5 14.0 31.0 10.6 .011
GARS (18–72) .8 2.2 1.8  5.4 1.0 .065
Results of t-test for independent samples.
SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; VAS, visual analog scale; SDQ, Shoulder Disability Questionnaire46;
GARS, Groningen Activity Restriction Scale.48
aNo standard deviations were given because it concerns a dichotomous variable.








(mean  SD) P value
Pain (VAS: 0–10) .4  1.1 .8 1.5 .4  1.7 .001
Numbness (n)a 0 119 119 .001
Forward flexion (°) 172.5  11.8 166.3 14.1 6.2  12.9 .001
Abduction (°) 167.7  22.7 152.0 31.7 15.7  28.8 .001
Abduction/external rotation (°) 87.0 6.8 79.4 14.4 7.6  13.4 .001
External rotation (°) 67.7  12.9 61.7 12.7 6.0  12.6 .001
Strength of shoulder abductors (Nm) 150.9  36.8 139.5 36.8 11.4  31.9 .001
Strength of elbow flexors (Nm) 179.5  41.2 179.5 38.0 .0  40.3 .999
Grip strength (Nm) 296.1  65.1 279.3 71.0 16.8  48.0 .001
Circumference of upper arm (cm) 26.8  3.0 27.5 3.2 .7  1.7 .001
Circumference of forearm (cm) 24.3  2.1 24.7 2.2 .4  1.0 .001
SDQ (0–100) 7.9  19.3 18.6 27.9 10.7  29.2 .001
GARS (18–72) 19.7  3.8 21.2 5.2 1.5  4.6 .001
VAS, visual analog scale; SDQ, Shoulder Disability Questionnaire47,48; GARS, Groningen Activity Restriction Scale.49,50
aNo standard deviations were given because it concerns a dichotomous variable.
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ADLs between t0 and t1 for independent variables: axil-
lary surgery (SLNB and ALND), surgery of the breast
(breast-conserving surgery and mastectomy), radiation of
the breast (no or yes), and radiation of the axilla (no or
yes) (Table 5). ALND was a significant factor in the
prediction of almost all mean changes in the performed
assessments of upper limb function and ADLs (Table 5).
Radiation of the axilla was also significant in four anal-
yses (Table 5).
DISCUSSION
This study showed significant upper limb morbidity
and associated ADL disabilities 1 year after treatment in
breast cancer patients undergoing SLNB, ALND, or
both. Patients undergoing SLNB had significantly less
upper limb morbidity and fewer ADL disabilities 1 year
after treatment compared with patients undergoing
ALND.
This outcome confirms the assumption that SLNB is a
less extensive surgical procedure that is associated with
less upper limb morbidity compared with ALND. Sev-
eral studies previously reported on morbidity after SLNB
and ALND.23,25–35 All studies reported less morbidity in
patients after SLNB compared with ALND. However,
there was considerable variability in study design. Only
four studies used a preoperative assessment.25,29,32,34 The
follow-up period varied from 2 weeks to 3 years after
surgical treatment.32,33 Also, the assessment instruments
varied from self-constructed questionnaires to physical
examinations and some validated questionnaires. ADLs
were assessed in only two studies.26,30
This study used a preoperative assessment. Addition-
ally several reliable and validated measurement instru-
ments were used to assess upper limb morbidity and
perceived disability/ADLs.40–42,44,46,48,49 In a recent sys-
tematic review, we emphasized the importance of the
baseline assessment.12 Preoperative assessment was also
used by Leidenius et al.32 and Peintinger et al.34 The first
study mentioned evaluated shoulder range of motion
before surgery and 2 weeks and 3 months after surgery.32
Differences in the prevalence of axillary web syndrome
(20% of patients with SLNB and 72% patients of ALND)
were held responsible for the differences in range of
motion. Contrary to our findings, a normal range of
motion was observed in almost all patients of both
groups after 3 months. In that study, the author described
only short-time morbidity.32 Peintinger et al.34 evaluated
TABLE 5. Prediction of mean change in upper limb function and activities of daily life between t0 and t1 by means of linear
regression analysis for independent variables: axillary surgery (SLNB  0, ALND  1), surgery of the breast (breast-conserving
surgery  0, mastectomy  1), radiation of the breast (no  0, yes  1), and radiation of the axilla (no  0, yes  1)
Dependent Independent  (95% CI) r2 Change
Forward flexion (°) ALND 4.9 (.9–8.9) .03
Constant 2.7 (.6 to 6.0)
Abduction (°) Radiation of axilla 19.5 (5.0–34.1) .05
ALND 11.6 (2.8–20.4) .03
Constant 5.6 (1.5 to 12.7)
Abduction/external rotation (°) Radiation of axilla 7.4 (.7–14.2) .03
Constant 6.8 (4.8–8.7)
External rotation (°) Radiation of axilla 7.2 (.8–13.6) .03
Constant 5.1 (3.3–7.0)
Strength of shoulder abductors (Nm) ALND 14.1 (4.4–23.8) .04
Constant 1.0 (7.1 to 9.1)
Grip strength (Nm) ALND 24.3 (9.3–39.3) .05
Constant .9 (13.3 to 11.6)
Circumference of upper arm (cm) ALND .6 (1.2 to .2) .03
Constant .3 (.7 to .1)
Circumference of forearm (cm) Radiation of axilla .6 (1.1 to .1) .03
Constant .4 (.5 to .2)
Shoulder Disability Questionnaire ALND 11.9 (20.9 to 2.9) .03
Mastectomy 9.1 (.5–17.6) .02
Constant 6.0 (13.8 to 1.7)
Only significant predictors are represented.
The larger the coefficient , the larger the contribution of the independent variable to the explanation of the dependent variable. The r2 change is
a measure for the explained variance of the dependent variable by the independent variables. One hundred times r2 change gives the percentage of
explained variance. For instance, “Constant” is the mean change in the range of motion (ROM) for abduction when a patient received SLNB. When
a patient received ALND, the mean ROM for abduction decreased another 11.6°, and when this patient also received radiation of the axilla, the mean
ROM for abduction decreased another 19.5°.
Abd  C  (.1)ALND  11.6  (.1)rad axilla  19.5
SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; CI, confidence interval.
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pain, range of motion, and perceived disability (Karnof-
sky performance status scale [KPS]), in addition to qual-
ity of life, before to 1 year after ALND/SLNB. Similar to
our results, they found significantly more pain (VAS),
numbness, and change of abduction and flexion in the
ALND group 1 year after treatment. In contrast to our
results, patients perceived no disabilities (KPS) 1 year
after treatment.34 Maybe this was caused by their rela-
tively small patient sample size (n  56) or the different
assessment instrument (KPS vs. SDQ/GARS). The KPS
might be less sensitive for detecting small changes.
Swenson et al.30 assessed the side effects of ALND and
SLNB with a self-constructed questionnaire (the Mea-
sure of Arm Symptom Survey) at 1, 6, and 12 months
after surgery. At 12 months, they found significant dif-
ferences in perceived pain, numbness, and limitations in
range of motion in favor of the SLNB patients but found
no difference between groups in interference with daily
life.30 The perceived disabilities in ADLs assessed in our
study were relatively mild. Shoulder-related perceived
disability assessed by the SDQ was significantly higher
in the ALND group compared with the SLNB group.
This significant difference was not found for the GARS.
Probably the effect of axillary dissection is stronger for
shoulder-related disabilities/ADLs than for disability in
ADLs in general.
The SLNB group had a more favorable outcome than
the ALND group with respect to adjuvant radiation on
the axilla, chemotherapy, and hormonal therapy (Table
1). Relatively few ALND patients (19 of 138; 14%)
received radiation on the axilla. Other studies reported
effects of radiation on the axilla on shoulder range of
motion.12,18,45,51,52 The fact that patients who received
radiation on the axilla naturally belonged to the ALND
group may influence the comparison between SLNB and
ALND concerning treatment-related morbidity.
Multivariate linear regression analysis to predict mean
change in upper limb function and ADLs between t0 and
t1 showed that ALND and radiation on the axilla were
significant factors in the prediction of impaired range of
motion (Table 5). Clinically, these findings indicate that
concerning the decrease in range of motion in shoulder
abduction, SLNB was responsible for 5.6° of the reduc-
tion, ALND was responsible for another 11.6°, and ra-
diation on the axilla was responsible for another 19.5°.
The effect of radiation on the axilla was most noteworthy
for shoulder abduction, combined abduction/external ro-
tation, and external rotation. These results suggest that
radiation on the axilla affects the shoulder range of
motion more than it affects muscle strength (Table 5).
This confirms the results of some other studies12,18,52 and
may be explained by radiation-induced subcutaneous
fibrosis affecting the range of motion.
ALND as a predictor of upper limb morbidity was
observed for forward flexion, abduction, strength of
shoulder abductors, grip strength, upper arm circumfer-
ence, and shoulder-related ADLs (SDQ). These results
confirm those of other studies in which the extent of
axillary treatment was related to late morbidity.12,15,33,52
CONCLUSION
Significant treatment-related upper limb morbidity
and associated ADL disabilities exist 1 year after SLNB
or ALND. Treatment-related morbidity and shoulder-
related perceived disability/ADLs (SDQ) are signifi-
cantly lower 1 year after SLNB compared with ALND.
ALND can predict upper limb morbidity and shoulder-
related perceived disability/ADLs. Additional radiation
on the axilla predicts a further decrease in shoulder range
of motion.
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